CN102495215B - Kit for quantitatively detecting tumor necrosis factor alpha - Google Patents
Kit for quantitatively detecting tumor necrosis factor alpha Download PDFInfo
- Publication number
- CN102495215B CN102495215B CN201110399728.2A CN201110399728A CN102495215B CN 102495215 B CN102495215 B CN 102495215B CN 201110399728 A CN201110399728 A CN 201110399728A CN 102495215 B CN102495215 B CN 102495215B
- Authority
- CN
- China
- Prior art keywords
- tnf
- container
- kit
- add
- magnetic bead
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 40
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title claims abstract description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 30
- 102000004190 Enzymes Human genes 0.000 claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- 238000007885 magnetic separation Methods 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 239000011324 bead Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000008213 purified water Substances 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 238000013016 damping Methods 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012744 reinforcing agent Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000007983 Tris buffer Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 150000001718 carbodiimides Chemical class 0.000 claims description 6
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- -1 TNF-α compound Chemical class 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 18
- 238000005516 engineering process Methods 0.000 abstract description 9
- 239000006249 magnetic particle Substances 0.000 abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 230000002860 competitive effect Effects 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 9
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Concentration | Add calibration object dilution volume | Add X volume |
A | V-A*V/X | A*V/X |
B | V-B*V/X | B*V/X |
C | V-C*V/X | C*V/X |
D | V-D*V/X | D*V/X |
E | V-E*V/X | E*V/X |
F | V-F*V/X | F*V/X |
Group | Control group (ng/ml) | Acute attack group (ng/ml) | Alleviation group (ng/ml) |
TNF-alpha content | 0.178±0.011 | 0.872±0.167 | 0.235±0.049 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110399728.2A CN102495215B (en) | 2011-12-06 | 2011-12-06 | Kit for quantitatively detecting tumor necrosis factor alpha |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110399728.2A CN102495215B (en) | 2011-12-06 | 2011-12-06 | Kit for quantitatively detecting tumor necrosis factor alpha |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102495215A CN102495215A (en) | 2012-06-13 |
CN102495215B true CN102495215B (en) | 2014-01-22 |
Family
ID=46187056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110399728.2A Expired - Fee Related CN102495215B (en) | 2011-12-06 | 2011-12-06 | Kit for quantitatively detecting tumor necrosis factor alpha |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102495215B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102998457B (en) * | 2012-07-12 | 2015-08-26 | 电子科技大学 | The Competitive assays enzyme-linked immune detection method of grass carp TNFa lpha |
CN103823064B (en) * | 2014-03-03 | 2016-05-25 | 中华人民共和国张家港出入境检验检疫局 | A kind of vomitoxin immue quantitative detection reagent box and using method thereof |
CN104198721B (en) * | 2014-07-28 | 2016-10-05 | 北京润诺思医疗科技有限公司 | The preparation of a kind of silica-based magnetic bead bond of GP73 (GP73) antigen and application |
CN105467137A (en) * | 2015-11-26 | 2016-04-06 | 北京豪迈生物工程有限公司 | Free human chorionic gonadotropin beta-subunit test kit and test method |
CN106918633B (en) * | 2017-04-24 | 2019-06-25 | 中国科学院苏州生物医学工程技术研究所 | The detection method of cytokine TNF-α based on aptamer and golden magnetic nano particle |
CN110672857A (en) * | 2019-10-10 | 2020-01-10 | 四川大学华西第二医院 | TNF-alpha high-sensitivity Elisa detection kit and use method and application thereof |
CN113552368A (en) * | 2021-07-21 | 2021-10-26 | 苏州立禾生物医学工程有限公司 | Tumor necrosis factor alpha detection kit and detection method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101377490A (en) * | 2007-08-30 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Magnetic microparticle separating chemiluminescence immune analysis determination reagent kit for detecting related sign object and preparing method thereof |
CN102016552A (en) * | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | Methods and compositions for highly sensitive detection of molecules |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110059445A1 (en) * | 2008-03-28 | 2011-03-10 | Paul Rutgeerts | Mucosal gene signatures |
-
2011
- 2011-12-06 CN CN201110399728.2A patent/CN102495215B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101377490A (en) * | 2007-08-30 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Magnetic microparticle separating chemiluminescence immune analysis determination reagent kit for detecting related sign object and preparing method thereof |
CN102016552A (en) * | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | Methods and compositions for highly sensitive detection of molecules |
Also Published As
Publication number | Publication date |
---|---|
CN102495215A (en) | 2012-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102495215B (en) | Kit for quantitatively detecting tumor necrosis factor alpha | |
CN104634980B (en) | The super quick detection kit of cardiac muscle troponin I and super quick detection method | |
CN101738473B (en) | Treponema pallidum antibody diagnostic kit and preparation method thereof | |
CN102072957B (en) | Hepatitis C virus antibody diagnostic kit and preparation method thereof | |
CN103353521B (en) | Method for determining contents of biological marker and DNA through direct-reading portable glucometer | |
CN101452001A (en) | Quantitative determination RBP4 kit by chemiluminescence magnetic enzymoimmune method | |
CN107543932A (en) | The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of calcitonin | |
CN103941021B (en) | Kit for detecting interleukin-6 and method for detecting interleukin-6 for non-diagnostic purpose | |
CN103076455B (en) | Quantitative detection serum amyloid A protein kit and Synthesis and applications thereof | |
CN102520176B (en) | Kit for quantitatively detecting interleukin 8 | |
CN103173420A (en) | Hybridoma cell capable of secreting anti-cardiac troponin I monoclonal antibodies and applications thereof | |
CN105842464B (en) | Joint based on up-converting phosphor technology quantitatively detects uNGAL and uCr device and preparation method thereof | |
CN105259354A (en) | Kit for detecting tuberculosis T cell release gamma-interferon and use method of kit | |
CN101320041B (en) | Colloidal gold method for fast quantitative determination of C-reaction protein and its application | |
CN101592660A (en) | Brucellosis indirect enzyme-linked immunosorbent assay milk humoral antibody detection kit | |
CN103048453B (en) | Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof | |
CN105424941B (en) | AKR1B10 albumen and the kit for liver cirrhosis diagnosis | |
CN107271692B (en) | Fluorescent microsphere for marking specific high-affinity recombinant antibody and application thereof | |
CN102103142B (en) | In-vitro assay method for thrombin-activatable fibrinolysis inhibitor (TAFI) content | |
CN103048477A (en) | Nanometer magnetic particle chemiluminescence detection kit for triiodothyronine as well as preparation method and detecting method of same | |
CN104569390A (en) | Quantitative detection method for gamma-interferon and kit | |
CN109633163B (en) | procalcitonin/C reactive protein two-in-one detection kit | |
CN104730231B (en) | A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof | |
CN111707825A (en) | Kit for combined detection of tumor markers MCT1 and MCT4, and preparation method and application thereof | |
CN109856076A (en) | Detect the composition and detection method of cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LI SHOUWEI Effective date: 20150227 Owner name: WUHAN ANNA NANO BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: REN QINGYUAN Effective date: 20150227 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 273400 LINYI, SHANDONG PROVINCE TO: 430000 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150227 Address after: 430000 East Lake Hubei New Technology Development Zone, Wuhan high tech Avenue, No. 666 Wuhan national biological industry base project B, C, D District R & D building B1 Patentee after: An Wuhan nano Biological Technology Co., Ltd. Address before: 273400 Department of clinical laboratory, Feixian County people's Hospital, 71 health Road, Shandong, Linyi, Feixian County Patentee before: Ren Qingyuan Patentee before: Li Shouwei |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181221 Address after: 430000 East Lake New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan Kersi Biotechnology Co., Ltd. Address before: 430000 Development Building B1 of Wuhan National Biological Industrial Base Project B, C and D, 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee before: An Wuhan nano Biological Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 Termination date: 20201206 |
|
CF01 | Termination of patent right due to non-payment of annual fee |